GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical ... applications for depemokimab have been accepted for review by the China National Medical (TASE:PMCN) Products Administration and submitted ...

Senior execs from the Chinese division of GSK have been accused by China's Public Security Bureau (PSB) of paying doctors and hospitals "to open new sales channels and increase drug revenues".

GSK plc announced that the China National Medical Products Administration has accepted for review the new drug application for the use of Nucala (mepolizumab), a monoclonal antibody that targets ...

Pharmaceutical majors AstraZeneca and GSK have partnered with competitor Takeda and nine suppliers to accelerate the adoption ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK ... he did say that anything coming out of Europe or China would obviously be fair game. The pharmaceutical companies ...

So, one of the milestones that I want to note right at the beginning of the article is that GSK announced that on January 28, 2025, regulatory authorities in China, Japan, and Europe accepted ...

GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $73 billion and impressive gross margins of 72%, announced today that the China National Medical (TASE ...

(Alliance News) - GSK PLC on Thursday said its monoclonal antibody Nucala, also known as mepolizumab, has been accepted for review in China. The London-based pharmaceutical company said the China ...

GSK plc (LSE/NYSE: LON:GSK), a prominent pharmaceutical company with a market capitalization of $73 billion and impressive gross margins of 72%, announced today that the China National Medical ...